- Home
- Equipment
- north america
- cancer specific antigen
Refine by
Cancer Specific Antigen Equipment Supplied In North America
10 equipment items found
Manufactured by:NexImmune, Inc. based inGaithersburg, MARYLAND (USA)
NexImmune’s AIM™ platform is the foundation for our unique approach to immunotherapy. Our AIM nanoparticle technology enables the development of immunotherapies that orchestrate specific T cell function and trigger a precise immune response against disease. An AIM™ Adoptive Cellular Therapy (ACT) product is manufactured using an AIM™ nanoparticle cocktail that contains ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
ADC (Antibody-drug conjugate) is a next-generation antibody-drug conjugate that has improved efficacy over existing antibodies. This drug combines the advantages of two factors: target specificity, which is a characteristic of an antibody, and cytotoxicity, which is a characteristic of a drug. Specifically, this is a technology focused on targeting and killing ...
Manufactured by:Aptevo Therapeutics based inSeattle, WASHINGTON (USA)
APVO603 is a dual agonist bispecific antibody employing a novel mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family. Dual targeting of 4-1BB and OX40 provides synergistic co-stimulation of T cells with the potential to amplify the cytotoxic function of activated T cells and NK cells, potentially leading to more robust anti-tumor ...
Manufactured by:Bio-Techne based inMinneapolis, MINNESOTA (USA)
Immune cell therapy is rapidly emerging as an important alternative for cancer treatment, as well as treatment of autoimmune disease. Also known as adoptive cell therapy or cellular immunotherapy, it supercharges an individual’s immune cells to fight disease. ...
Manufactured by:Adicet Bio based inMenlo Park, CALIFORNIA (USA)
Gamma delta T cells represent a new generation of universal cell therapy. The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet to be proven. The cell platform and novel targeting approaches Adicet is developing are aimed at harnessing the tumor specific immunity of gamma delta ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
2’3’-c-di-AM(PS)2 (Rp,Rp) (ADU-S100), an activator of stimulator of interferon genes (STING), leads to potent and systemic tumor regression and ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
2’3’-c-di-AM(PS)2 (Rp,Rp) disodium salt (ADU-S100 disodium salt) is an activator of stimulator of interferon genes ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
2’3’-c-di-AM(PS)2 (Rp,Rp) ammonium salt (ADU-S100 ammonium salt), an activator of stimulator of interferon genes (STING), leads to potent and systemic tumor regression and ...
by:Metaclipse Therapeutics Corporation based inAtlanta, GEORGIA (US) (USA)
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ prepared from a patient’s tumor tissue that Metaclipse modifies with a ‘protein transfer’ method using ...
Manufactured by:Lineage Cell Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
VAC2 is an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase which is commonly expressed in cancerous cells but not in normal adult cells. VAC2, which is produced from our pluripotent cell technology using a directed differentiation method, is comprised of a population ...